Physician profile
Alan D Jensen
NPI 1053495614
$3,336.80
in general payments reported to CMS, 2019-2025
26 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $524 · 2021: $266 · 2022: $480 · 2023: $490 · 2024: $470 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $629.47 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $492.60 | 2019-2023 | |
| Abbvie INC. | $386.23 | 2022-2025 | |
| Allergan, INC. | $302.75 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $213.80 | 2019-2023 | |
| Amgen INC. | $181.49 | 2020-2023 | Otezla, Repatha |
| Avadel Cns Pharmaceuticals, LLC | $136.56 | 2025 | Lumryz |
| Idorsia Pharmaceuticals US INC | $124.90 | 2024 | Quviviq |
| Axsome Therapeutics, INC. | $104.12 | 2023-2025 | Auvelity |
| Forte Bio-Pharma LLC | $103.99 | 2022-2023 | |
| Amarin Pharma, INC. | $90.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $71.42 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.13 | 2022-2025 | Caplyta |
| Almatica Pharma LLC | $60.05 | 2021-2025 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $56.40 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $43.11 | 2024 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $40.53 | 2020-2025 | Nexletol |
| Halozyme INC | $39.63 | 2023 | |
| Lilly USA, LLC | $35.16 | 2022-2023 | |
| Novo Nordisk INC | $32.80 | 2020-2025 | Ozempic |
| Collegium Pharmaceutical, INC. | $29.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $27.90 | 2024 | Breztri |
| Supernus Pharmaceuticals, INC. | $24.89 | 2023 | Xyosted, Qelbree, Tlando |
| Lundbeck LLC | $22.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.63 | 2023 | Trulance, Xifaxan |
| Qol Medical, LLC | $7.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.